Molecular Profiles of Smokers with Subclinical Interstitial Lung Disease
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease poor survival, limited treatment options and no known cure. Recent groundbreaking clinical trials have shown that antifibrotic therapies can attenuate the decline in lung function particularly in IPF patients with mild interstitial lung disease (ILD).These remarkable findings support the concept that early detection of ILD could improve clinical outcomes by increasing secondary prevention opportunities. Accordingly, a recent NHLBI sponsored panel on the Primary Prevention of Lung Disease highlighted the need to better understand the natural history of early stages of pulmonary fibrosis in order to identify modifiable risk factors and in turn develop timely interventions to prevent disease progression. To address this important unmet need, the panel concluded that initial research efforts should focus on better defining phenotypic and molecular traits associated with subclinical ILD in susceptible populations. In this proposal we will prospectively study a large cohort of smokers enrolled in the Pittsburgh Lung Screening Study (PLuSS). Our study related objectives were to develop and deploy an image analytic approach that allows the objective interpretation of low radiation dose CT scans. We then proposed to explore the clinical associations of the data we extracted from those scans. Finally, we sought to use those data as well as additional clinical and biologic information to identify people at greatest risk for the development of advanced parenchymal lung disease.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2023
- Accession Number
- AD1220642
Entities
People
- George Washko
Organizations
- Brigham and Women's Hospital